Format

Send to

Choose Destination
Curr Opin Mol Ther. 2005 Dec;7(6):588-97.

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Author information

1
Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA. michael.morse@duke.edu

Abstract

Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.

PMID:
16370382
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center